Review demonstrates changes in glycolysis and its implications for spinal cord injury treatment, highlighting therapeutic targeting and metabolic regulation.
Spinal cord injury (SCI) is a severe neurological disorder that not only causes significant physical and psychological harm to patients but also imposes a substantial economic burden on families and society. Following SCI, a cascade of secondary events occurs, including inflammatory responses, scar formation, and mitochondrial dysfunction. Numerous studies have demonstrated that glycolysis plays a crucial role in the pathophysiological changes post-SCI and may serve as a promising therapeutic target for future SCI treatments. This account systematically summarizes the alterations in glycolysis after SCI, focusing on three key aspects: the activation pathways of glycolysis, changes in metabolic rates and metabolites, and the expression levels of related enzymes and molecules. Furthermore, it highlights the mechanisms by which glycolysis-targeted interventions promote SCI repair, including modulation of inflammatory responses, oxidative stress, apoptosis, and axonal regeneration. Additionally, the applications and limitations of glycolysis-targeting drugs and other emerging therapeutic approaches are critically analyzed. Finally, this review outlines preliminary achievements and prospects in the clinical translation of glycolysis-targeted therapies for SCI. This review summarizes the mechanisms underlying the regulation of glycolysis-targeting SCI, along with current major therapeutic strategies and associated challenges, thereby offering potential insights into the treatment of SCI.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: